Tralokinumab-ldrm Therapeutic Cheat Sheet
162811628116281
Atopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c …
Atopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c … Continue reading "Tralokinumab-ldrm Therapeutic Cheat Sheet"
Dermatologists are prescribing oral glucocorticoids for psoriasis despite awareness of risks of life-threatening generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). A recent survey of dermatologists published in the Journal of Drugs in Dermatology found 18% of respondents occasionally prescribe oral glucocorticoids to patients with psoriasis, typically 1-5% of the time. Those wh … 
Dr. Lawrence F. Eichenfield, meeting co-chair for the 17th Annual Women’s and Pediatric Dermatology Seminar, kicked off session III with a superb talk titled “Scaling the Heights…and Below, Pediatric Scaling Diseases: Psoriasis and Others”, giving us a bird’s eye view on the old and the new regarding pediatric psoriasis.
Dr. Eichenfield is a complete rock star and served as a valued … 
Dr. Shari Lipner, Associate Professor of Clinical Dermatology and Director of the Nail Division at Weill Cornell Medicine and President of The Dermatologic Society of Greater New York, shared her expertise of nail disorders in patients with skin of color: from nail psoriasis and onychomycosis to subungual melanoma.
Dr. Lipner’s lecture focused on the following key points (spoiler alert!):
… 
The following two cases presented by JDD authors Ryan A. Gall MD, John D. Peters MD, and Alyson J. Brinker MD add to the growing literature supporting the use of dupilumab in the treatment of patients with recalcitrant dyshidrotic eczema, both with and without diagnosed contact allergens.
Introduction
Dyshidrotic eczema, also known as dyshidrosis or pompholyx when involving larger bullae, is a c … 